FDA approves oral treatment for ulcerative colitisPfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis. Share XFDA approves oral treatment for ulcerative colitishttps://pharmaphorum.com/news/fda-oral-treatment-ulcerative-colitis/